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1. Introduction 
 
 
Trastuzumab (Herceptin ® , Roche)  is approved in UK for the treatment of the metastatic breast 
cancer since 2001. As of 2005, concomitantly with the publication of 3 studies that showed it 
produces a 50% reduction of the recurrence rates of breast cancer, trastuzumab started to be 
prescribed in the early adjuvant treatment of this disease. Until June 2006, trastuzumab did not have 
both: 1) regulatory approval and 2) NICE recommendation for the use in early stages of breast 
cancer. During this period until June 2006, the trastuzumab use in those patients was not 
reimbursed and because the cost of trastuzumab is equal with the yearly UK average income, most 
of patients could not self fund their treatment. 
 
Before the publication of the final NICE guidance, the new data of trastuzumab in early breast 
cancer raised enormous patient and professional interest and expectations. A great volume of public 
and professional pressure was generated to transcend a system by which Primary Care Trusts can 
reimburse a treatment only after a formal guidance was issued. 
 
This paper draw on a case study depicting and analyzing the process by which regulatory 
approval and NICE recommendations were achieved in a record time and how trastuzumab became 
a standard treatment on early adjuvant breast cancer. According to the data we gathered in this work 
we were witnessing one of the fastest processes of adoption of a health care technology since the 
creation of NICE, in 1999. This study addresses the following research question:  How and why 
does the adoption pattern of trastuzumab differ from the rational decision-making model of the 
reimbursement process in UK?  
 
 
 
 
 
 
2. Theoretical Background. 
 
A number of adoption models are described in the literature.  
The rational model explained by Rogers 1 (Rogers et all, 2005) and Abrahamson 2 proposes that the 
adoption of an innovation depends mainly on the strength of the scientific evidence backing it. This 
objective evidence comprises arguments of technical efficiency and is accepted in a smooth manner 
by passive stakeholders  - the diffusion of the innovation is depicted as a smooth, rational process. It 
is the relative advantage of the innovation compared to the currently existing technologies that drives 
the pace of the process. The passive nature of the actors and the incontestability of the evidence are 
the major characteristics of those models. 
 
Abrahamson 2 describes an institutional model where the adopting institutions have a deciding, 
coercitive role on its components. The innovation is accepted through imitation of external 
organizations which launch the “fashions” or through the imitation of other internal units of the 
same organization that already adopted it – “the fads”. The process of adoption is passive and linear. 
 
The political model is promoted by Denis and colleagues (Denis et. Al, 2002).3 They argued that 
the diffusion of an innovation is a nonlinear process and showed that the scientific evidence has only 
a limited influence on the final outcome.  Maguire (2002) shows the extreme fluidity of the political 
model and arguments that in the adoption process both the adoption system and the innovation 
undergo changes.4 
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Gelijns et al. (2005) show that it is the blend of scientific evidence and politics that make the final 
result and the institutions that are responsible for adopting the innovations have to master the 
synthesis between science and politics. 5 
 
The trastuzumab adoption case appears to be one of “over adoption” that is when the scientific 
evidence lags behind the speed and actual achievement of adoption. 3 Despite the lack of a full 
appraisal process and of regulatory clearance for its use in early breast cancer, physicians prescribed 
the drug and patients were fighting publicly for its free availability from the moment of publication in 
June 2005 of the preliminary results of 3 combined trials showing trastuzumab’s activity in this 
disease area. 
 
The final outcome – the NICE guidance -  occurred as a result of a negotiation between the 
various stakeholders involved in the adoption process and we had a special interest in understanding 
their actions and motivations along this process. We found that, compared to a classical adoption 
model, the number and the influence of the key players changed during the process.  
 
 
 
3. Methodology 
 
For our longitudinal case study, occurring between June 2005 and June 2006, in a chronological 
order, we selected and studied for each and one of the actors involved in the trastuzumab adoption 
process, their most important actions, decisions, public statements that were of relevance for the 
final decision of NICE to recommend the use of trastuzumab in the treatment of early stage breast 
cancer. As major sources of information we used articles published in the medical and the lay press in 
the period and also news bulletins from major news organizations such as BBC. 
 
It was by understanding the chronological order of those actions that we clarified the changes 
occured in the trastuzumab adoption process vs. the previous adoption and diffusion cases.   
Finally, after analyzing our findings we launched our  proposed responses for the study question. 
 
 
 
 
 
4. BREAST CANCER 
 
The breast cancer is the most common malignancy in women. Worldwide, there are 1 million new 
cases every year. The incidence and mortality rates for breast cancer in UK are among the highest in 
the world. Overall, breast cancer accounts for 18% of all female cancers and there are 62.6 death per 
100,000 population every year 6 (figure 1). 
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Fig.1 Standardized mortality for breast cancer in different countries (copyright BMJ 2000; 321: 624) 
 
 
The past decade has seen an impressive decrease (of approximately 15% ) in the breast cancer 
mortality rates in UK, despite a raising incidence of this disease.7 Experts consider that the wide 
diffusion of the adjuvant (post surgical) systemic therapy is the main responsible for this positive 
trend. 7-10  
 
Polichemotherapy, endocrine therapy and trastuzumab are part of today’s drug armamentarium 
in the treatment of early breast cancer. 7-10They all reduce tumor recurrence and mortality yearly rates 
7-10. However, between various drugs exists significant differences in terms of clinical efficacy and 
side effects profile. In that perspective, major differences exist between the older therapies – 
chemotherapy and tamoxifens and the newer ones - aromatase inhibitors and trastuzumab. 7 -10 The 
efficacy gains are reflected in reduced risk of disease recurrence and overall prolongation of patient 
lives, whereas the side effect profile gains are mostly translated in improved quality of patient lives. 
All those benefits are considered fundamentals by physicians and their patients and explain the great 
expectations and interest for the new generation of drug therapies. 
 
The access to the new drug treatments varies greatly across countries. US, Switzerland, Austria 
and France seem to be the countries with the most rapid adoption and diffusion rates of the newest 
breast cancer drug treatments such as trastuzumab, whereas UK together with Norway and countries 
from Central Europe display adoption rates bellow the average. 11 Within the same country, 
geographical variations of drug diffusion are reported as well. In UK, a study found a variation of up 
to 12-fold in the rate of prescribing for chemotherapy drugs appraised by NICE at that time. 12 
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In the last period, the free access to the new cancer therapies became a major subject of medical, 
political, economical, and societal debate in UK. The future of the national drug research and 
development, the political aspects regarding the quality of the governance of the national health 
service (NHS), the role and the extent of the society in supporting particular needy individuals are 
among the fundamental points of this debate. 13, 14, 15  
 
It is in this dynamic context that we studied the adoption and diffusion of trastuzumab in the 
treatment of early breast cancer. That event had structural consequences for the future shape of the 
adoption and diffusion process of a medical innovation in UK. The institutions in charge with the 
adoption, the process of adoption and the innovation itself underwent significant changes by the end 
of this story. 
 
 
This case study exhibits the evolution and contribution of a number of key players who had an 
important role in the final outcome - the guidance of NICE for reimbursement of trastuzumab 
prescribed in the treatment of the early stage breast cancer patients.  
 
 
 
 
 
5. The Innovation: Trastuzumab (Herceptin®) 
 
 
 
 
Trastuzumab is a recombinant monoclonal antibody (Herceptin, Roche) that was approved by the 
European Agency for the Evaluation of Medicinal Products (EMEA) in August 2000 for the 
treatment of patients with metastatic breast cancer whose tumors over express the human epidermal 
growth factor receptor 2 (HER2), which is normally involved in the regulation of cell proliferation. 16 
Over expression (abnormal increase in numbers) of the HER2 receptor occurs in 25-30% of the 
patients with primary breast cancer and is a prognostic factor for poor survival rates. 17  
In June 2006, EMEA approved trastuzumab for the treatment of patients with HER2 positive early 
breast cancer following surgery, chemotherapy (neoadjuvant or adjuvant) and radiotherapy (if 
applicable).  
According to the license granted by EMEA, Herceptin should only be used in patients whose tumors 
have either HER2 overexpression or HER2 gene amplification as determined by an accurate and 
validated assay. 16  
 
The license was granted on the basis of 3 large randomized clinical trials which found hazard 
ratios for breast cancer recurrence of 0.48 when trastuzumab combined with chemotherapy was 
compared with chemotherapy alone, and 0.54 when the trastuzumab treatment was compared with a 
control intervention, meaning that trastuzumab contributed to reducing the risk of disease come back 
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by percentages between 48 and 54%. 18-20 At one year, the disease free survival rates were 85.8% with 
trastuzumab vs. 77.4% in the control arm, hence an absolute benefit of almost 8%. 
 
Reported survival benefits were between 0 and  4.8% at four years.18-20  
The recent publication of the results of 2 years follow up of the HERA trial (trastuzumab after 
adjuvant chemotherapy vs. chemotherapy alone) showed a survival benefit of  2.7% vs. the control 
group.71 With all these, because trastuzumab was found to halve the breast cancer recurrence rates, 
the results of the trials were considered “not evolutionary but revolutionary.”21 
The number needed to treat (NNT) found in one of the 3 trials were 19, meaning that 19 
patients need a treatment in order to prevent one recurrence.23 In an analysis performed at the level 
of the Norfolk and Norwich University Hospital it was shown that for funding the treatment of 75 
patients eligible for trastuzumab it was needed an amount of money that could fund otherwise the 
adjuvant treatment of 355 patients and the palliative treatment of another 30 patients with various 
cancers. For the overall population size of the trust, the analysis was showing that 3 extra patients 
would be cured with trastuzumab vs. 16 in case of the other combined treatments. 24 
A significant finding was the increased risk of cardiac toxicity, incidence of which ranged from 
0.5% to 4.1% in the 3 clinical trials.22 That triggers the need of regular cardiac monitoring hence 
increased treatment costs. Additional costs should be considered for the treatment of those adverse 
cardiac events that result in patient morbidity and reduced quality of life. 23  
 
The trastuzumab yearly average cost per person varies between £24,000 and £28,000. 24  
More costs should be considered, knowing that patients are to be tested for the HER2 receptor 
overexpression. From the 35,000 women with early breast cancer in UK, 20,000 would be suitable 
for testing for HER2 receptor. Approximately 20% would be eligible for treatment with trastuzumab. 
Nation wise, that would raise the cost of treatment at over £100m if the treatment with trastuzumab 
will be given to all eligible patients. 25 
At the time of publication of the new trastuzumab data, in UK more than a quarter of women 
were never tested for HER2 overexpression and only half were tested at the time of the initial 
diagnosis. 23 
 
5. The rational process and its guardian: NICE 
 
NICE (National Institute for Health and Clinical Excellence) produces national guidance on health 
technologies, public health and clinical practice. The guidance issued by NICE is required to be 
implemented by the NHS organizations in England and Wales within 3 months of issue. 26 
NICE appraises the clinical and cost effectiveness of health technologies referred to it by the 
Department of Health. The process is complex, involves many interested parties (stakeholders) and 
usually takes around two years to complete. 27  
The critics of the NICE appraisal process say that this delay can allow patterns of treatment of 
uncertain cost effectiveness to be established. The eventual licensing of other treatments during the 
appraisal period may render the guidance outdated (NICE. Draft Scope - Macular degeneration (age-
related). 28  
 
 
Following is a brief description of NICE the appraisal process,  
(Adapted from: Developing NICE Technology Appraisals. 
http://www.nice.org.uk/page.aspx?o=114218)  29: 
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1. Selection of the provisional appraisal topics. 
The Department of Health (DH) produces a list of provisional appraisal topics. 
2. Identification of the consultees and commentators. 
This includes: national organisations, groups representing patients and carers, bodies 
representing health professionals, manufacturers and research groups.  
3. Preparation of the scope. 
NICE works with the DH to develop a scope. This document establishes what the appraisal will 
cover and the questions that need to be asked. Consultees and commentators comment on the 
draft scope.  
4. Referral of the appraisal topic. 
The Department of Health refers technology appraisal topics to NICE.  
5. Preparation of the assessment report. 
An independent academic centre reviews published evidence on the technology and prepares an 
assessment report. Consultees and commentators comment on the report.  
6. Preparation of the Evaluation report. 
This includes the assessment report and comments the comments received. 
7. Production of the Appraisal consultation document (ACD). 
An independent appraisal committee considers the evaluation report. It hears evidence from 
nominated clinical experts, patients and carers and than generates the ACD.  The ACD is made 
available online for comment from  health professionals and public.  
8. Final appraisal determination (FAD). 
The independent appraisal committee considers the comments on the ACD, then makes its 
final recommendations in the FAD. The FAD is submitted to NICE for approval. In this phase 
consultees can appeal against the final recommendations in the FAD. 
9. Final Guidance. 
If there are no appeals, or an appeal is not upheld, the final recommendations are issued as 
NICE guidance. 
 
In September – November 2005, because of the great time lengths taken for appraising life 
saving drugs, and under the enormous pressure from the public and government generated by the 
trastuzumab case, NICE decided to short cut its own assessment timelines and developed and had 
approved “the single technology appraisal” process (STA). 30  
Trastuzumab was the first lifesaving drug to benefit from an appraisal period of about 4 months: 
in February 2006 the evidence was submitted by the manufacturers and in June 2006 NICE 
published the draft guidance.  Few years before, the appraisal process for the adoption of 
trastuzumab in metastatic breast cancer lasted for 14 months, after EMEA approved the license. (A 
full chronology of the trastuzumab adoption process is described in ANNEX A). 
 
 
 
Overview of the STA process  
(Adapted from: Guide to the Single Technology Appraisal Process. September 2006. Appendix B. 
Available at: http://www.nice.org.uk/page.aspx?o=STAprocessguide) 31 
 
The STA process, from referral to the publication of guidance, consists of three distinct phases: 
Phase1: NICE will notify the manufacturer/sponsor of the STA and request an evidence submission. 
Delay: min 8 weeks. 
Phase 2: the Evidence Review Group’s work (a minimum of 8 weeks), appraisal of the evidence and 
preparation of the recommendations.  
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Phase 3: a Final Appraisal Determination (FAD) document is issued containing the 
recommendations. Delay: between 7 and 15 weeks. Following release of a FAD, consultees have 15 
working days to appeal.  
In case no appeals are received, it will take between 32 weeks and 39 weeks to produce the 
guidance. (pls. see Annex B  for the description of the STA timelines).  
 
As described above, in the STA process, the evidence is submitted only by manufacturer of the 
drug, followed by an independent assessment by the institute and the issuing of the draft guidance. 
At this stage an appeal against the decision can be formulated by the interested organizations.32  
 
There are three grounds on which stakeholders may appeal against a draft guidance: 1) process 
(due process), 2) perversity (given evidence), and 3) powers (exceeding its powers). A panel 
composed of 5 non executive NICE members, industry and patient representatives will hear the 
appeal. On the ground related to the due process  an appellant may appeal if it believes the appraisal 
process was not a fair one, i.e. if not all data sets submitted were taken in consideration.  
On the ground related to the given evidence one may appeal if it considers the decision in conflict or 
simply wrong in the light of the submitted evidence. 
On the ground related to exceeded powers, the appeal may be founded on the consideration that 
NICE went over the attributions stated in its Statutory Instruments or simply that it acted unlawfully 
under the current legal frame (NICE: Appraisal Process: Guidance for Appellants). 33  
 
NICE does not have a threshold at which cost effectiveness becomes acceptable but most of the 
assessments done until now indicate that for incremental cost effectiveness ratios  above £20,000 / 
QALY the case supporting the respective technology has to be increasingly strong. 26, 34  
Beyond this cost effectiveness analysis, the appraisals do not explicitly consider the affordability of 
the technologies within the NHS and NICE does not provide extrafunding or does not advise on 
additional source of funding for the adoption of the new technology. 35  
 
In a review article on the health service reform in UK, Maynard and Street found that NICE is 
confronted with four main issues: 1) technologies are approved on marginal cost effectiveness 
generating increased NHS spending for small health gains of the population, 2) there is failure in 
removal of the old, redundant technologies, 3) there is uneven implementation of the guidances 
across the country and 4) NICE lacks negotiation power over prices. On those grounds the authors 
conclude that NICE cannot fulfill its rationing function. 13  
 
 
7. Main players on the trastuzumab adoption scene:  
7.1. Politicians 
Setting public health as a priority on the political agenda is a key of government’s and individual 
politician’s success nowadays. In this context, members of the UK parliament frequently embrace 
popular cases such as supporting cancer patients.   
A statistic of the House of Commons question book showed 84 questions on trastuzumab by April 
2006. 36  
The Secretary of State  for Health, Patricia Hewitt had frequent and decisive public interventions 
during the trastuzumab debate: 
1.
  “I have asked for a fast track appraisal of the use of Herceptin in parallel with the licensing 
process” 37 (October 2005) 
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2.
 “Herceptin has the potential to save many women's lives and I want to see it in widespread 
use on the NHS”.38  (October 2005) 
3.
 "Today I am asking Prof Mike Richards to ensure that the facilities are put in place to enable 
women who require it to be tested.”38(October 2005) 
4.
 "I want the license for Herceptin to be granted as quickly as possible, without compromising 
people's safety, and to be available within weeks of the licence being given”.38 (October 
2005) 
5.
 "I share the huge frustration of many women about the delays in getting Herceptin licensed. 
I am determined to take action and this represents a major step forward in our fight against 
cancer."38 (October 2005) 
6.
 All women with early stage breast cancer would be tested for suitability for treatment with 
trastuzumab. “Testing now should mean women could receive the drug as soon as the 
licence is extended, probably next year”39 (October 2005) 
7.
 Primary health care trusts “should not refuse to fund Herceptin (trastuzumab) solely on the 
grounds of its cost”40 (November 2005) 
8.
 “PCTs should not rule out treatments on principle but consider individual circonstances”40  
(November 2005) 
 
In a visit to Manchester in November 2005, asked about the trastuzumab funding by the Primary 
Care Trusts, prime minister Toni Blair said: “primary care trusts should go ahead and allow people to 
use it (trastuzumab)”. 41 
The government interference over Herceptin appraisal by NICE received strong criticism. In a public 
intervention Iain Chalmers, founder of Cochrane Library, raised doubts over the capability of the 
government to see over the individual cases, thus compromising NICE’s work.42 
 
 
 
7.2. Media  
All throughout the period in study,  media was a permanent supporter of the patients in need for 
trastuzumab treatment. It generously offered the public platform to show the fight of individual 
patients in need of treatment, to quote statements coming from various advocacy groups and it was 
a permanent critic of the lengthy formal drug approval processes. In the period, there were reports 
from patients who were called by media outlets and were offered support in terms of pressing for 
obtaining funding for trastuzumab in exchange of rendering public their own personal stories.43 
By carrying with perseverance a number of  exemplar patient cases together with stories about 
“the wonder drug” prepared in the so called press releases, the media succeeded to maintain 
continuous public attention and pressure on authorities. 37  During the period January 2005 – 
December 2006, The Sun had 94 articles and press releases mentioning trastuzumab (Herceptin ®), 
in most cases centered on patients individual stories. 44 
The attitude of media towards the trastuzumab case was called “hyperbolic” and some authors 
have criticized the intense public pressures under which NICE had to deliberate on the file as a case 
of  “rationing by media”.35 
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In the trastuzumab case the media showed the validity and the great influencing power of  the 
“rule of rescue”, which is defined as a perceived duty to save endangered individual life wherever 
possible (NICE citizen council report – Rule of Rescue).45 
This intense media campaign generated high emotional reactions on the breast cancer patients 
themselves and drove them to engage in an increasing stream of public actions.43 
 
 
STAKEHOLDERS of the NICE Appraisal process 
 
7.3. Patient, Associations, Advocacy groups 
The public actions of this group of stakeholders can be classified in two periods: prior 2006, when 
decisions of PCTs to refuse trastuzumab funding were appealed by patients and the result with no 
exception was the granting of treatment, and during 2006, when for the first time a patient brought 
her case to court. All those cases received wide public coverage and we could establish their 
chronology from the various press articles we had in our documentation. 
In October 2005, nurse Barbara Clark, 49, threatened Somerset Coast Primary Care Trust with 
a Judicial Review, but the Trust backed-down before the case and provided her with the treatment. 
The appeal to the exceptional treatment panel of the Somerset Coast Primary Care Trust was 
grounded on patient’s exceptional circumstances -  Mrs. Clark has a child with a life limiting 
condition. Barbara Clark was the first patient to go public in her fight for the treatment.46, 47 
In November 2005, Elaine Barber. North Stoke PCT reversed an initial decision not to fund 
trastuzumab, after discussions between the patient and the trust chief’s executive and after the 
release of a press statement by the health secretary that the trust ruling was in conflict with other 
trusts decisions 48, 49 
Amanda D’Argue and Alyson Cooper were among few other patients who received funding 
for their treatment following public actions against the ruling of their trusts.50 
The case of the 7 patients from North Staffordhire who organized an advocacy group called 
“Fighting for Herceptin” (see photo 1 and 2) was also widely publicized. Eventually all of them 
received the funding for their treatment before the end of their campaigning program. 51  “Fighting 
for Herceptin” group started their activity soon after June 2005 by meetings with the local health 
authorities. They appeared in national papers, on BBC programmes, they organized tens of events, 
collected signatures for their campaign and eventually arrived to manifest in front of Downing Street 
10 on September 2005. 52 (photo 1 and 2) 
Photo 1: “Fighting for Herceptin” in front of Downing Street 10. 
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Ann Marie Rogers. 
This is the most mediatized patient case in the whole cohort of individual stories regarding early 
breast cancer patients in quest for treatment with  trastuzumab.  
Ann Marie Rogers was the first patient to go to court in Britain, in a trial to force the NHS to 
fund her treatment with trastuzumab. The case received wide national press coverage and the story 
was reported closely by media outlets such as BBC news, SKY News, The Sun, but also medical 
press like British Medical Journal.  
1. In January 2006 Ann Marie Rogers, received the right to appeal against a decision by 
Swindon Primary Care Trust to refuse the treatment with trastuzumab. The judge ordered 
Swindon PCT to fund the treatment until a full court hearing. 
2. In February 2006 the hearing takes place at a High Court in London. Ann Marie Rogers 
claims that Swindon PCT is breaching her human rights in refusing to fund the treatment. 
As well, she claimed that the trust operated “an arbitrary, irrational and unlawful policy” 
against the decisions of the Department of Health. Mrs. Rogers considered that the decision 
of Swindon PCT is “equal with a death sentence”36.  
3. The High Court Judge rejected the appeal, deciding that Swindon’s PCT decision was not 
unlawful, nor was it a breach of the European Convention of Human Rights.  
4. The judge gave Mrs. Rogers permission to appeal and ordered Swindon PCT to pay for the 
treatment on an interim basis until the appeal court’s decision. 
5. In April 2006, Ann Marie Rogers brought her case to the London Appeal Court. The judges 
unanimously ruled that Swindon PCT has acted irrationally and unlawfully in refusing 
treatment to Ann Marie Rogers. The ruling stated that once the cost was considered 
irrelevant to the funding decision, the PCTs should fund all patients who could benefit from 
treatment. On the contrary, if cost was a constraint, then PCTs would act lawfully by 
deciding to reserve funding for other exceptional cases. 
Exactly at the same time and under this public pressure NICE was running the Single 
Technology Appraisal process for the evidence of clinical cost effectiveness of trastuzumab in the 
early breast cancer. Meantime, in Bruxelles, the EMEA regulatory approval process was taking place.  
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Foto 2: Press article  - Fighting for Herceptin 
 
Cancerbackup ( http://www.cancerbackup.org.uk/Home) , Breaktrough Breast Cancer ( 
http://www.breakthrough.org.uk/ ) and Breast Cancer Care  
(http://www.breastcancercare.org.uk/ ) were among the numerous advocacy groups that sustained 
publicly and with high voice the trastuzumab funding fight in 2005 and 2006.  
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1. In a general statement about the length of NICE’s approval process, the Chief Executive of 
Cancerbackup declared: “cancer treatment should be examined within 3 months of a license 
being granted”.54 
2. Immediately after the news of Ann Marie Rogers’s winning appeal, the Chief Executive of 
Breaktrough Breast Cancer said publicly: “It is vital that this decision is now reinforced by 
NICE guidance being issued this summer. The fast track approval of drugs by NICE is 
welcomed but we need to ensure that once approved, guidance is implemented fully and that 
patients receive the drugs recommended”55.  
3. At the news of trastuzumab being granted the licence for use in the early stages of breast 
cancer, the spokesman of the Breakthrough Cancer charity reacted: “this is great news and 
should persuade any hesitating doctor or primary care trust to offer Herceptin to suitable 
patients. The full licence confirms Herceptin is safe and effective in early breast cancer”56 
Patient groups provided support and information to patients and the public all the period we 
have in our study. As well, the 3 patient groups mentioned above were actively involved in the 
NICE appraisal process of trastuzumab as stakeholders and representatives of patients and patients 
organizations. 24  
There is a growing public debate about the societal role and the influence of the patients group 
in their actions for wider treatment access. Medical authors launch warnings on the damages 
generated by “the access advocacy”, through which the pharmaceutical companies would weaken 
research, licensing and appraisal.57 
Official voices sustain that the funding relation between drug companies and the advocacy 
groups in the future “will do the patient organizations an immense amount of damage and the 
confidence in their neutrality will dissipate” – Michael Rawlins, chairman of NICE. 58 
Recent surveys show that between 33 and 60% of the European patient groups receive industry 
funding. 58  It is not clear how big is this financial support and neither if it may undermine the 
group’s independence.  
Directly related to our case, Cancerbackup, one of the most active advocates of trastuzumab 
public funding, declared publicly that 9% of its financial resources are from industry. 58 
In an online survey conducted this year by BMJ, the following results were recorded to the 
question: “should patient groups accept money from the pharmaceutical industry?”: 16% responded 
yes and 84% said no. 59 
Beyond that debate, it is obvious that the overwhelming part of the advocacy work is done in 
moral integrity and with a great educational role for the large public. The patient advocacy may be 
seen today as the link between a public with little knowledge and understanding of the theoretical 
aspects of the health matters and health professionals and policy makers that are looking to obtain 
scientific evidence for evidence based decisions. 60 
 
7.4. Opinion Leaders.  
As a public voice, their role in generating interest and high expectations of the treatment was 
quintessential. Their declarations ranged from calls for moderation, balanced approach and thorough 
analysis of all elements in the play, with an increased accent towards considering the safety profile of 
the drug and the lack of strong evidence for efficacy markers 61 to ecstatic, enthusiastic vis à vis of 
the introduction of a drug that seemed to be a milestone in the treatment of breast cancer, years after 
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the introduction of taxanes. 21 Their comments and articles fueled the medical press during the 
period and were constant sources of references for the lay press. 
 
7.5. Practicing physicians.  
This category of stakeholders had rather a low public profile along the whole adoption process. 
Undoubtedly, an enormous amount of dialogue took place between the practicing clinicians and 
their patients in the meantime, regarding the efficacy and the appropriateness of this drug in 
individual situations. This generated expectation and request from the patient side for the early 
adoption of the treatment. 
 
 7.6. NHS (National Health Service) 
NHS includes 152 regional primary care trusts (PCTs) that commission health services for a 
population of up to about 600,000. 
NHS spends £10.3 bn a year on drugs and costs are raising rapidly. 62  
It is considered today that NHS resources are overexploited through a phenomenon termed “the 
tragedy of commons” – individual patients are acting rationally in seeking expensive treatments that 
generate marginal health benefits, because the costs fall on the common resource of NHS. 14  
At the end of 2005 the NHS had debts of around £620m for the financial year, with 
approximately 5% of the primary care trusts being responsible for the biggest part of the deficit. In 
this context, the intervention of the secretary of state for health in favor of free funding of 
trastuzumab to an individual patient went highly criticized in parliament.63 
Prior trastuzumab case, the NHS organizations were little involved in the NICE appraisal 
process, most probably because of their low capacity for assessing effectiveness and prioritization. 
Realizing that they will be confronted with dramatic resource allocation decisions, the Primary Care 
Trusts, via the trastuzumab appraisal process, became active players in the adoption and seem more 
prepared to contribute to it by offering to the NICE appraisal the wider perspective, beyond the cost 
effectiveness assessments of the individual drugs. 24  
 
 
7.7. The drug company. 
According to the STA rules, Roche was the sole source of the clinical and cost effectiveness evidence 
for the current appraisal. 24 An independent review has followed, however, in the process, the 
manufacturer was asked to submit only the evidence that it considered appropriate. 
In the period, Roche sponsored health enconomic publications related to population access to 
newest cancer therapies. A 2005 sponsored report of the Karolinska Institute was republished 2 years 
later and was highly echoed by the UK lay media.70 The report criticizes NICE for not enabling faster 
access of the medicines to the UK market (Wilking N, Jonsson B, 2005).64 
 
There is relatively scarce public evidence of the relation between the drug company and patients 
or advocacy group in our case. Except the public declaration of funding made by the Cancerbackup 
organization, we retrieved Roche in a public spot when Professor Lisa Jardine, a patient with breast 
cancer herself, accused the company that tried to persuade her to run a public fight for free access to 
the treatment.65 Roche denied the accusations and seems to have gone off the public stage for the 
period until submission of the evidence for the extension of their drug license, in February 2006.   
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. 
8. END OF PROCESS AND  IMPLICATIONS OF THE TRASTUZUMAB CASE. 
 
In June 2006, 2 weeks after trastuzumab received approval for use in early breast cancer by EMEA, 
NICE published the draft guidance for England and Wales. Separate guidance for Scotland was 
issued the previous week by the Scottish Medicines Commission. 66  
The drug is recommended as a treatment option for women with early stage HER2 positive breast 
cancer after surgery, chemotherapy and radiotherapy, if applicable. 66  
 
In July 2006 Newbury and Community Primary Care Trust appealed against the draft guidance. 
The appellants declared that they did not want to prevent the use of the drug but they asked 
clarification on the following points: 1) type of HER2 patients who should receive the treatment 2) 
the appropriate moment of start of treatment 3) the length of the treatment 4) the impact on the 
NHS resources 5) the long term risk and benefits of trastuzumab. 24 
 
In August 2006 a NICE panel dismissed the appeal and issued the final guidance for use of 
trastuzumab in early breast cancer. 67 However, NICE included in the final guidance responses to 
several points of the appeal clarifying aspects related to the start of treatment and the type of 
patients. 24 
The final guidance recommends the use of trastuzumab based on findings that the drug is clinical 
and cost effective. The guidance recommends 3 weeks cycles of treatment for one year or until 
recurrence, whichever is the shorter period. The guidance recommends cardiac function assessment 
and limits the drug use in patients at cardiovascular risk.24 
 
The marginal cost per quality adjusted life year was found to be in the range of £3400 for the 
weekly dose regimen. Reviewing the data for the metastatic breast cancer, the evidence review group 
found that the marginal cost per QALY gained in this setting is ranging from £16,000 to £33,000. 24 
 
 
 
8.1. Implications of the trastuzumab adoption process:  
 
1. NICE decided to short cut its own assessment timelines and developed “the single technology 
appraisal” process. A whole cohort of cancer medicines are to benefit from the process, so we can 
say that from that perspective the adoption process of trastuzumab was a revolutionary one. 
 
2. The single technology appraisal process is taking place during and not after the regulatory 
review and that contributes massively to the shortening of the appraisal duration. 
 
3. The trastuzumab case provoked a heated public debate about the NHS current functioning. It 
re stated the responsibilities of the local PCT management in making rational use of resources and 
the role of NICE as provider of guidance and support tools for economic decisions. It put the spot 
on the need of  resource re allocation by the promotion of generic substitution and the possibility of 
introduction of a new drug reimbursement system. 68  
 
4. The innovation itself and more explicitly the evidence that was subject of the NICE 
independent review was submitted only by the manufacturer, and the nature and quality of it 
depended solely on the manufacturer’s judgment of appropriateness. The innovation itself suffered 
changes in the adoption process: there is now a “ test” for trastuzumab – that is mandatory for 
patients prior treatment and it predicts treatment success. 
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5. The industry funding of the patient organizations went in to a more in-depth scrutiny in that 
period. The Association of British Pharmaceutical Industry called for its members to disclose charity 
funding. Voices are raising in favor of stricter national regulations for charities and disclosure of the 
relation between charities and industry is now requested.58  
 
6. The rule of rescue. The trastuzumab adoption process provoked a highly moral and 
philosophical debate about the fundaments and the role of the society in saving distressed individuals 
life vs. more rational use of resources for ensuring “the greatest good for the greatest number”. The 
NICE Citizen Report Rule of Rescue was published in January 2006, in the midst of the trastuzumab 
public storm. 45 
 
 
 
9. FINDINGS AND THEORY BUILDING 
 
 
What type of adoption and diffusion model can we recognize in the  trastuzumab case? 
Are we in the “efficient choice perspective” (Abrahamson, 1991)2  where all NHS organizations were 
convinced of the effectiveness of the drug? Was the decision to reimburse trastuzumab rational?  
In the run of this process, the scientific evidence was lagging behind adoption and ambiguity 
regarding the effectiveness of trastuzumab persisted for the whole period during which free access to 
this drug was granted to few individual patients. Therefore, at all times before NICE final guidance, 
we would define our case as one of over adoption. (Denis et al., 2002) 3 
 
The Department of Health’s statement that the funding decisions of trastuzumab should not be 
based on cost arguments solely, but should consider the individual circumstances, recalls the intense 
public pressure the health system had to face in this period. From a model perspective, that situation 
recalls rather the Abrahamson’s paradox, where organizations are in search of “political efficiency” 
instead of “technical efficiency”. According to it, a technically inefficient innovation which is 
supported by external groups will be adopted if the political costs of not conforming to external 
pressures will exceed the technical costs of adopting it. 2  In our case the political cost for a 
government would have been that of loosing popularity and for NICE of increased government 
scrutiny and pressure. 
 
A coalition of actors with highly different backgrounds emerged to defend the fast adoption of 
trastuzumab. It was by a common reading of the associated risk and benefits and by sharing the same 
value judgements that the group of patients, advocacy associations, politicians and industry managed 
to break the reluctance of a system that was installed to be a guardian of evidence-based decisions.   
 
During this period a series of Primary Care Trusts decided to fund trastuzumab based on the fact 
that other trusts decided to do so. It is the classical “fad perspective” from the Abrahamson model 2, 
where organizations unsure about the efficiency of the innovation are relying on prior decisions of 
similar organizations and thus are looking for legitimacy. 
 
In the same period, a final judgement of an Appeal court together with some rulings of the 
Secretary of State for Health, made us look more closely at the “forced-selection perspective” from 
Abrahamson’s diffusion model. 2 
 
Undoubtedly, the final decision of adoption and its speed was influenced by the high public 
profiles of the individual patient cases of “exceptional” nature.  
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The fact that various Primary Care Trusts funded at different times in that period the treatment 
based on the existence of “exceptional circumstances” tends to confirm the proposal by Denis et al. 3 
according to which the process of diffusion is a matter of negotiation of this periphery - in our case 
regarding the economic decision and the indications of use.  
 
In order to reach the conclusion that trastuzumab is an effective option in the treatment of the 
early-stage breast cancer, the adopting institution, the appraisal process and the innovation itself 
suffered a  number of significant structural changes (see implications). 
that were the result of intense negotiations, therefore the current trastuzumab adoption model moves 
closely to the political fluid model described by Maguire.2  
 
 
 
10. CONCLUSIONS  
 
Back to our research questions, we found that the context of the adoption process has changed and 
this change was the ferment of further process changes.  The theories of rational models, being 
centered on the overwhelming role of the scientific evidence and on the decisive influencing power 
of adopting institutions are clearly of limited relevance. Today’s context of adoption decisions is 
characterized by 1) increased quantity and quality of the information flow, 2) efficient informal 
networking that conveys education and information on public health issues, and 3) an increased 
number of participants conscious of their societal roles. With the diminishing role of the scientific 
evidence, the external financial, political and emotional pressures become the key decision factors. In 
this context, the trastuzumab adoption process was one of high fluidity, with multilocular decision 
making and of greatly accelerated speed.  It was a dynamic process with multiple variables: place of 
decision making, number and influence of the various stakeholders. The nature of the innovation 
coupled with the set of values and goals of the players had the most important role in the final 
decision of the adoption. 
 
The structure of the adoption process and the timelines suffered changes when the clash 
between the strong rational arguments and the value judgments based on moral and emotions 
occurred. The dynamic of those changes reflects and parallels the dynamic of the deep societal 
changes, therefore we believe for the future that there cannot be given adoption processes for long 
period of times, only a common frame of negotiation could be agreed upon. 
 
Moreover, the adoption process of a health technology tends to be an ever rolling process, since 
once with wider uses, doctors and patients are tempted to seek utility of a treatment in other disease 
areas. 
 
Today, a health care adoption system is required extreme elasticity – since at the moment of 
adoption it is not prepared to absorb the new innovation  - see the costs of adoption of trastuzumab 
and the need to refuse other important cancer treatments in order to accommodate the budgetary 
changes. Under those circumstances the system leaves a continuous process of adaptation and the 
long term outcomes in terms of resource allocation of a specific adoption decision are difficult to 
predict on a strictly rational basis.  
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12. ANNEX A 
 
Chronology of trastuzumab adoption milestones. 
Adapted from BMJ (Wells J, Cheong-Leen C. NICE appraisals should be everyone’s business. BMJ 
2007; 334:936-8) and Bulletin de Cancer (Buron C et all. Reflexion on innovation diffusion factors: 
the case of Herceptin. Bull Cancerr vol94, n3, mars 2007) 
 
 
March 1998: FDA decides “fast track approval procedure” for trastuzumab. Development 
of a test for identification of patients eligible for trastuzumab therapy 
July 1998: Presentation at ASCO of phase III clinical trial results showing trastuzumab in 
association with chemotherapy slows disease progression and increases tumour shrinkage in 
patients with metastatic breast cancer 
September 1998: US FDA approval of use of trastuzumab in the treatment of metastatic 
breast cancer HER2 positive patients 
August 1999: Switzerland becomes the first European country to approve the 
commercialization of trastuzumab 
August 2000: EMEA approval of use of trastuzumab in the treatment of metastatic breast 
cancer HER2 positive patients 
December 2000: Genenetech/Roche in collaboration with other industry cancer therapy 
leaders launch phase III clinical trials to evaluate the efficacy of trastuzumab in adjuvant 
treatment of the breast cancer 
March 2002: NICE approves trastuzumab for metastatic breast cancer 
August 2002: Genentech receives FDA approval to insert label information concerning the 
FISH test for detecting the breast cancer gene 
May 2005: Abstracts of preliminary results from trials of trastuzumab in early breast cancer 
presented at American Society for Clinical Oncology conference 
June 2005- October 2005: Various public actions from patients and patient associations 
against decisions of PCTs to refuse funding of treatment with trastuzumab. 
September 2005: NICE announces a new approval process for life saving drugs, labeled 
Single Technology Appraisal  
October 2005: Secretary of State for Health, Patricia Hewitt demands publicly a fast track 
NICE approval process for trastuzumab  
October 2005: A few patients receive NHS funded treatment for early breast cancer as 
"exceptional" cases, some after high profile appeal actions 
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November 2005:   Publication in NEJM  of the final  results of 3 trials evidencing an 
improvement on overall survival rates, disease free survival rates in Herceptin breast cancer 
treated patients in adjuvant setting 
January –April 2006: Judicial action of Ann Marie Rogers against Swindon Primary Care 
Trust  
February 2006: Roche applies for a European license for the drug to be used "for the 
treatment of patients with HER2 positive early breast cancer following surgery, 
chemotherapy . . . and radiotherapy (if applicable)"  
June 2006:  EMEA grants license for use in early breast cancer 
June 2006: NICE publishes draft guidance on use in early stage breast cancer after a single 
technology appraisal for trastuzumab 
July 2006: Newbury and Community Primary Care Trusts appeals against NICE draft 
guidance on the use of trastuzumab 
August 2006: NICE rejects appeal and publishes final trastuzumab approval and guidance 
requiring NHS  implementation within 3 months.6  
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13. ANNEX B 
Timelines of the STA process. Guide to the Single Technology Appraisal Process. September 2006. 
Appendix B. Available at: http://www.nice.org.uk/page.aspx?o=STAprocessguide  
 
 
 
